Oryzon Genomics - FRIDA funding and orphan drug designation
Oryzon Genomics has been awarded a $2m public grant to support its ongoing Phase Ib FRIDA clinical study. This follows recent FDA approval of its...
671 Views
Oryzon Genomics - Planning iadademstat’s path to market
Oryzon is making progress with its two epigenetic drugs, iadademstat for oncology and vafidemstat for CNS indications (both are lysine-specific...
1k Views
Oryzon Genomics - Large response benefit consistent in ALICE trial
On 11 June 2021, Oryzon presented an updated set of data from the Phase IIa ALICE trial in acute myeloid leukaemia (AML) at the virtual Congress of...
909 Views
Oryzon Genomics - Final update from Phase IIa CLEPSIDRA trial
On 17 September Oryzon presented an update from its Phase IIa CLEPSIDRA trial with iadademstat, a selective LSD1 inhibitor, in combination with...
169 Views
Oryzon Genomics - Third positive update from Phase II ALICE trial
Last Friday, Oryzon presented an updated set of data from the Phase IIa ALICE trial in acute myeloid leukaemia (AML) at the virtual 25th Congress...
110 Views